Trade ARCA Biopharma - ABIO CFD
Market information is presented
as of 2023-09-21
- Summary
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 1.85-2.70 |
| Average Volume (10 days) | 22.87K |
| Average Volume (3 months) | 477.94K |
| Market Cap | 29.40M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 14.41M |
| Revenue | N/A |
| EPS | -0.44 |
| Dividend (Yield %) | N/A |
| Beta | 1.28 |
| Next Earnings Date | Oct 26, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
ARCA Biopharma Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, October 26, 2023 | ||
| Time (UTC) 10:59 | Country US
| Event Q3 2023 ARCA Biopharma Inc Earnings Release Q3 2023 ARCA Biopharma Inc Earnings ReleaseForecast -Previous - |
| Thursday, February 22, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 ARCA Biopharma Inc Earnings Release Q4 2023 ARCA Biopharma Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 10.596 | 19.335 | 9.766 | 5.814 | 8.118 |
| Selling/General/Admin. Expenses, Total | 5.847 | 5.503 | 4.774 | 3.981 | 3.879 |
| Research & Development | 4.749 | 13.832 | 4.992 | 1.833 | 4.239 |
| Operating Income | -10.596 | -19.335 | -9.766 | -5.814 | -8.118 |
| Interest Income (Expense), Net Non-Operating | 0.675 | 0.013 | 0.019 | 0.165 | 0.154 |
| Net Income Before Taxes | -9.926 | -19.322 | -9.747 | -5.649 | -7.964 |
| Net Income After Taxes | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
| Net Income Before Extra. Items | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
| Net Income | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
| Income Available to Common Excl. Extra. Items | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
| Income Available to Common Incl. Extra. Items | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
| Diluted Net Income | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
| Diluted Weighted Average Shares | 14.4101 | 13.9039 | 4.71024 | 1.32123 | 0.76939 |
| Diluted EPS Excluding Extraordinary Items | -0.68882 | -1.38968 | -2.06741 | -4.14915 | -10.3107 |
| Diluted Normalized EPS | -0.68882 | -1.38968 | -2.06741 | -4.14915 | -10.3107 |
| Other, Net | -0.005 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 1.973 | 1.796 | 1.548 | 2.552 | 3.219 |
| Selling/General/Admin. Expenses, Total | 1.719 | 1.406 | 1.487 | 1.528 | 1.734 |
| Research & Development | 0.254 | 0.39 | 0.061 | 1.024 | 1.485 |
| Operating Income | -1.973 | -1.796 | -1.548 | -2.552 | -3.219 |
| Interest Income (Expense), Net Non-Operating | 0.493 | 0.45 | 0.374 | 0.222 | 0.072 |
| Net Income Before Taxes | -1.48 | -1.346 | -1.174 | -2.333 | -3.147 |
| Net Income After Taxes | -1.48 | -1.346 | -1.174 | -2.333 | -3.147 |
| Net Income Before Extra. Items | -1.48 | -1.346 | -1.174 | -2.333 | -3.147 |
| Net Income | -1.48 | -1.346 | -1.174 | -2.333 | -3.147 |
| Income Available to Common Excl. Extra. Items | -1.48 | -1.346 | -1.174 | -2.333 | -3.147 |
| Income Available to Common Incl. Extra. Items | -1.48 | -1.346 | -1.174 | -2.333 | -3.147 |
| Diluted Net Income | -1.48 | -1.346 | -1.174 | -2.333 | -3.147 |
| Diluted Weighted Average Shares | 14.4101 | 14.4101 | 14.4101 | 14.4101 | 14.4101 |
| Diluted EPS Excluding Extraordinary Items | -0.10271 | -0.09341 | -0.08147 | -0.1619 | -0.21839 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.10271 | -0.09341 | -0.08147 | -0.1619 | -0.21839 |
| Other, Net | 0 | 0 | 0 | -0.003 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 42.699 | 54.421 | 49.968 | 8.48 | 6.777 |
| Cash and Short Term Investments | 42.445 | 53.359 | 49.071 | 8.363 | 6.608 |
| Cash & Equivalents | 42.445 | 53.359 | 49.071 | 8.363 | 6.608 |
| Short Term Investments | 0 | ||||
| Other Current Assets, Total | 0.254 | 1.062 | 0.897 | 0.117 | 0.169 |
| Total Assets | 43.085 | 54.924 | 50.429 | 8.536 | 6.825 |
| Property/Plant/Equipment, Total - Net | 0.368 | 0.485 | 0.449 | 0.032 | 0.024 |
| Property/Plant/Equipment, Total - Gross | 0.572 | 0.68 | 0.699 | 0.399 | 0.398 |
| Accumulated Depreciation, Total | -0.204 | -0.195 | -0.25 | -0.367 | -0.374 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 0.018 | 0.018 | 0.012 | 0.024 | 0.024 |
| Total Current Liabilities | 1.132 | 3.498 | 3.499 | 0.926 | 0.793 |
| Accounts Payable | 0.334 | 1.117 | 1.773 | 0.418 | 0.23 |
| Accrued Expenses | 0.798 | 2.381 | 1.726 | 0.508 | 0.563 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.412 | 3.881 | 3.908 | 0.926 | 0.793 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.28 | 0.383 | 0.409 | 0 | |
| Total Equity | 41.673 | 51.043 | 46.521 | 7.61 | 6.032 |
| Common Stock | 0.014 | 0.014 | 0.01 | 0.002 | 0.014 |
| Additional Paid-In Capital | 225.061 | 224.505 | 200.665 | 152.024 | 144.952 |
| Retained Earnings (Accumulated Deficit) | -183.402 | -173.476 | -154.154 | -144.416 | -138.934 |
| Other Equity, Total | |||||
| Total Liabilities & Shareholders’ Equity | 43.085 | 54.924 | 50.429 | 8.536 | 6.825 |
| Total Common Shares Outstanding | 14.4101 | 14.4101 | 9.54815 | 1.59407 | 0.77356 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 41.702 | 42.699 | 44.55 | 47.655 | 50.539 |
| Cash and Short Term Investments | 40.85 | 42.445 | 43.939 | 46.437 | 49.059 |
| Cash & Equivalents | 40.85 | 42.445 | 43.939 | 46.437 | 49.059 |
| Other Current Assets, Total | 0.852 | 0.254 | 0.611 | 1.218 | 1.48 |
| Total Assets | 42.059 | 43.085 | 44.965 | 48.101 | 51.014 |
| Property/Plant/Equipment, Total - Net | 0.339 | 0.368 | 0.397 | 0.428 | 0.457 |
| Property/Plant/Equipment, Total - Gross | 0.547 | 0.572 | 0.598 | 0.632 | 0.655 |
| Accumulated Depreciation, Total | -0.208 | -0.204 | -0.201 | -0.204 | -0.198 |
| Other Long Term Assets, Total | 0.018 | 0.018 | 0.018 | 0.018 | 0.018 |
| Total Current Liabilities | 1.266 | 1.132 | 1.937 | 2.809 | 2.719 |
| Accounts Payable | 0.366 | 0.334 | 0.593 | 1.11 | 1.014 |
| Accrued Expenses | 0.9 | 0.798 | 1.344 | 1.699 | 1.705 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.528 | 1.412 | 2.238 | 3.138 | 3.076 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.262 | 0.28 | 0.301 | 0.329 | 0.357 |
| Total Equity | 40.531 | 41.673 | 42.727 | 44.963 | 47.938 |
| Common Stock | 0.014 | 0.014 | 0.014 | 0.014 | 0.014 |
| Additional Paid-In Capital | 225.265 | 225.061 | 224.941 | 224.844 | 224.672 |
| Retained Earnings (Accumulated Deficit) | -184.748 | -183.402 | -182.228 | -179.895 | -176.748 |
| Total Liabilities & Shareholders’ Equity | 42.059 | 43.085 | 44.965 | 48.101 | 51.014 |
| Total Common Shares Outstanding | 14.4101 | 14.4101 | 14.4101 | 14.4101 | 14.4101 |
| Preferred Stock - Non Redeemable, Net | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -9.926 | -19.322 | -9.738 | -5.482 | -7.933 |
| Cash From Operating Activities | -10.912 | -18.762 | -7.725 | -4.801 | -8.244 |
| Cash From Operating Activities | 0.02 | 0.016 | 0.008 | 0.018 | 0.022 |
| Non-Cash Items | 0.655 | 0.572 | 0.128 | 0.222 | 0.275 |
| Cash Interest Paid | 0 | 0 | 0.009 | 0.007 | 0.008 |
| Changes in Working Capital | -1.661 | -0.028 | 1.877 | 0.441 | -0.608 |
| Cash From Investing Activities | -0.002 | -0.043 | -0.019 | -0.004 | 3.046 |
| Capital Expenditures | -0.002 | -0.043 | -0.019 | -0.004 | -0.004 |
| Other Investing Cash Flow Items, Total | 0 | 3.05 | |||
| Cash From Financing Activities | 0 | 23.093 | 48.452 | 6.56 | 3.104 |
| Financing Cash Flow Items | 0 | -0.977 | -2.034 | -0.372 | -0.117 |
| Issuance (Retirement) of Stock, Net | 0 | 24.07 | 50.894 | 7.281 | 3.532 |
| Issuance (Retirement) of Debt, Net | 0 | -0.408 | -0.349 | -0.311 | |
| Net Change in Cash | -10.914 | 4.288 | 40.708 | 1.755 | -2.094 |
| Cash Taxes Paid | 0 | 0 | 0.009 | -0.167 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -1.346 | -9.926 | -8.752 | -6.419 | -3.272 |
| Cash From Operating Activities | -1.595 | -10.912 | -9.418 | -6.92 | -4.298 |
| Cash From Operating Activities | 0.004 | 0.02 | 0.015 | 0.011 | 0.005 |
| Non-Cash Items | 0.229 | 0.655 | 0.511 | 0.387 | 0.192 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Cash Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Changes in Working Capital | -0.482 | -1.661 | -1.192 | -0.899 | -1.223 |
| Cash From Investing Activities | 0 | -0.002 | -0.002 | -0.002 | -0.002 |
| Capital Expenditures | 0 | -0.002 | -0.002 | -0.002 | -0.002 |
| Cash From Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | 0 |
| Issuance (Retirement) of Stock, Net | 0 | 0 | 0 | 0 | |
| Net Change in Cash | -1.595 | -10.914 | -9.42 | -6.922 | -4.3 |
| Issuance (Retirement) of Debt, Net |
ARCA Biopharma Company profile
About Arca Biopharma Inc
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro(bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. Gencaro(bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. AF is the form of cardiac arrhythmia, a disruption of the heart’s normal rhythm or rate. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19. It is also conducting Phase IIB/III clinical trial of Gencaro.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Arca Biopharma Inc revenues was not reported. Net loss increased 98% to $19.3M. Higher net loss reflects Other -Research and development increase from $5M to $13.7M (expense), other expenses1 increase of 8% to $5.1M (expense), Stock-based Compensation in SGA increase from $17K to $337K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.07 to -$1.39.
Equity composition
Common Stock $.001 Par, Insiders own 3.59% . IPO 8/97, 3M shares @$14 by LehmanBrothers, Inc. PO 3/04, 5M shares @ $13 by UBS SecuritiesLLC. 2/03, Company merged with Variagenics, Inc. andchanged name from Hyseq, Inc. 01/09, Name changed fromNuvelo, Inc. 03/13, 1-for-6 reverse stock split. 9/15, 1-for-7 reverse stock split.
| Industry: | Bio Therapeutic Drugs |
Suite 430
8001 Arista Place
BROOMFIELD
COLORADO 80021
US
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com